Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not re ...

Iovance Biotherapeutics, Inc. (IOVA) incurred a first-quarter 2025 loss of 36 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company reported a loss of 42 cents per share.Quarterly revenues totaled $49.3 million, entirely from the sales of its two marketed drugs. This figure missed the Zacks Consensus Estimate of $80.5 million. In the year-ago quarter, Iovance recorded total revenues of $0.7 million. (Find the latest EPS estimates and surprises o ...

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.27 per share when it actually produced a loss of $0.26, delivering a surprise of 3.70%.Over the last four quarters, the c ...

Iovance Biotherapeutics (IOVA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day and thank you for standing by. Welcome to the Iovance Biotherapeutics First Quarter twenty twenty five Financial Results Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will press 11 on your telephone. You will then hear an automated message advising your hand is raised. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-36860 IOVANCE BIOTHERAPEUTICS, INC. (Exact name of issuer as specified in its charter) (State or other jurisdiction of (I. ...

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Registrational Trial in Previously Treated Advanced NSCLC in 2H25 SAN CARLOS, Calif., May 8, 2025 -- Iovance Biother ...

1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Registrational Trialin Previously Treated Advanced NSCLC in 2H25 SAN CARLOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, ...

SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. ...

SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C-144-01 stud ...

Core Viewpoint - Iovance Biotherapeutics has an approved drug, Amtagvi, for treating unresectable or metastatic melanoma, but its stock has significantly declined, raising concerns among investors about its future performance [1][2]. Group 1: Stock Performance and Market Sentiment - Iovance's stock has fallen approximately 57% since the beginning of the year as of April 22, indicating a significant sell-off [5]. - The percentage of short-sellers in relation to Iovance's float has been increasing, reflecting growing skepticism about the company's future success [3]. Group 2: Financial Health and Cash Flow - Iovance is experiencing poor cash flow, which may lead to further dilution for shareholders as the company has historically relied on issuing stock to fund operations [11]. - As of the end of 2024, Iovance had cash and short-term investments totaling $323.8 million, but ongoing high cash burn could deplete this cushion over time [10]. Group 3: Future Revenue Potential - Although Amtagvi has the potential to generate $1 billion in annual revenue, this is not expected until 2030, which raises concerns about the company's ability to achieve profitability in the near term [7][12]. - Iovance reported a net loss of $372.2 million last year, highlighting the financial challenges it faces [12].